Trivant Custom Portfolio Group, LLC Avidity Biosciences, Inc. Transaction History
Trivant Custom Portfolio Group, LLC
- $174 Billion
- Q1 2025
A detailed history of Trivant Custom Portfolio Group, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Trivant Custom Portfolio Group, LLC holds 100 shares of RNA stock, worth $3,826. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$3,826% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
247Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$437 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$434 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$371 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$354 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$335 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.99B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...